| Literature DB >> 35262738 |
Samuel M Rubinstein1, Divaya Bhutani2, Ryan C Lynch3, Jeremy L Warner4,5, Michael A Thompson6, Chih-Yuan Hsu7, Yu Shyr7,4, Shailesh Advani8, Ruben A Mesa9, Sanjay Mishra10, Daniel P Mundt6, Dimpy P Shah9, R Alejandro Sica11, Keith E Stockerl-Goldstein12, Catherine Stratton13, Matthias Weiss14, Alicia Beeghly-Fadiel4, Melissa Accordino2, Sarit E Assouline15, Joy Awosika16, Ziad Bakouny17, Babar Bashir18, Stephanie Berg19, Mehmet Asim Bilen20, Cecilia A Castellano20, Jacob C Cogan2, Devendra Kc21, Christopher R Friese22, Shilpa Gupta23, Daniel Hausrath10, Clara Hwang24, Nathalie A Johnson15, Monika Joshi25, Anup Kasi26, Elizabeth J Klein27, Vadim S Koshkin28, Nicole M Kuderer29, Daniel H Kwon28, Chris Labaki17, Tahir Latif16, Eric Lau30, Xuanyi Li10, Gary H Lyman31, Rana R McKay32, Gayathri Nagaraj30, Amanda Nizam23, Taylor K Nonato32, Adam J Olszewski27, Hyma V Polimera25, Andrew J Portuguese3, Matthew M Puc33, Pedram Razavi32, Rachel Rosovski34, Andrew Schmidt17, Sumit A Shah35, Aditi Shastri11, Christopher Su22, Pallawi Torka36, Trisha M Wise-Draper16, Leyre Zubiri33.
Abstract
Patients with B-lymphoid malignancies have been consistently identified as a population at high risk of severe COVID-19. Whether this is exclusively due to cancer-related deficits in humoral and cellular immunity, or whether risk of severe COVID-19 is increased by anticancer therapy, is uncertain. Using data derived from the COVID-19 and Cancer Consortium (CCC19), we show that patients treated for B-lymphoid malignancies have an increased risk of severe COVID-19 compared with control populations of patients with non-B-lymphoid malignancies. Among patients with B-lymphoid malignancies, those who received anticancer therapy within 12 months of COVID-19 diagnosis experienced increased COVID-19 severity compared with patients with non-recently treated B-lymphoid malignancies, after adjustment for cancer status and several other prognostic factors. Our findings suggest that patients recently treated for a B-lymphoid malignancy are at uniquely high risk for severe COVID-19. SIGNIFICANCE: Our study suggests that recent therapy for a B-lymphoid malignancy is an independent risk factor for COVID-19 severity. These findings provide rationale to develop mitigation strategies targeted at the uniquely high-risk population of patients with recently treated B-lymphoid malignancies. This article is highlighted in the In This Issue feature, p. 171. ©2022 American Association for Cancer Research.Entities:
Mesh：
Year: 2022 PMID： 35262738 PMCID： PMC9355598 DOI： 10.1158/2643-3230.BCD-22-0013
Source DB: PubMed Journal: Blood Cancer Discov ISSN： 2643-3230